Novan Inc
F:6LUA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Nex Metals Explorations Ltd
ASX:NME
|
AU |
Novan Inc
Total Receivables
Novan Inc
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Novan Inc
F:6LUA
|
Total Receivables
$22m
|
CAGR 3-Years
274%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Total Receivables
$17.2B
|
CAGR 3-Years
2%
|
CAGR 5-Years
5%
|
CAGR 10-Years
5%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Total Receivables
$14.5B
|
CAGR 3-Years
1%
|
CAGR 5-Years
11%
|
CAGR 10-Years
13%
|
|
|
Pfizer Inc
NYSE:PFE
|
Total Receivables
$15.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
15%
|
CAGR 10-Years
7%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Total Receivables
$12.7B
|
CAGR 3-Years
8%
|
CAGR 5-Years
10%
|
CAGR 10-Years
7%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Total Receivables
$20.2B
|
CAGR 3-Years
33%
|
CAGR 5-Years
24%
|
CAGR 10-Years
17%
|
|
Novan Inc
Glance View
Novan, Inc. is a biotechnology company, which engages in leveraging nitric oxide’s natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. The company is headquartered in Durham, North Carolina and currently employs 29 full-time employees. The company went IPO on 2016-09-21. The firm is engaged in researching, developing and marketing products for skin diseases. The firm is focused on dermatology and anti-infective therapies. Its technology platform leverages nitric oxide’s naturally occurring anti-viral, anti-bacterial, anti-fungal, and immunomodulatory mechanisms of action to treat a range of diseases. The firm has clinical-stage dermatology and anti-infective drug candidates with multi-factorial (SB204), anti-viral (SB206), anti-fungal (SB208), and anti-inflammatory (SB414) mechanisms of action. The Company’s lead product candidate is SB206, which is a topical gel with anti-viral properties for the treatment of viral skin infections, with focus on molluscum contagiosum. The firm is exploring the potential of its NITRICIL technology as a potential treatment option for COVID-19, targeting the reduction of viral shedding and transmission.
See Also
What is Novan Inc's Total Receivables?
Total Receivables
22m
USD
Based on the financial report for Dec 31, 2022, Novan Inc's Total Receivables amounts to 22m USD.
What is Novan Inc's Total Receivables growth rate?
Total Receivables CAGR 3Y
274%
Over the last year, the Total Receivables growth was 392%. The average annual Total Receivables growth rates for Novan Inc have been 274% over the past three years .
